{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:30:59Z","timestamp":1789047059776,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science and Technology Major Project of Infectious Diseases","award":["2017ZX10304402"],"award-info":[{"award-number":["2017ZX10304402"]}]},{"name":"National Science and Technology Major Projects for Major New Drugs Innovation and Development","award":["2018ZX09711003-005-003"],"award-info":[{"award-number":["2018ZX09711003-005-003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31670933"],"award-info":[{"award-number":["31670933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801646"],"award-info":[{"award-number":["81801646"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.antiviral.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T16:46:31Z","timestamp":1541781991000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential"],"prefix":"10.1016","volume":"161","author":[{"given":"Bing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5665","authenticated-orcid":false,"given":"Longfa","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangtao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruopeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2335","authenticated-orcid":false,"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfa","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.11.001_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00430-016-0465-y","article-title":"Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy","volume":"205","author":"Aswathyraj","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib2","doi-asserted-by":"crossref","first-page":"O150","DOI":"10.1111\/1469-0691.12361","article-title":"Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain","volume":"20","author":"Cabrerizo","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2018.11.001_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-1759(00)00339-2","article-title":"Bispecific human IgG by design","volume":"248","author":"Carter","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2018.11.001_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2018.11.001_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jviromet.2015.02.010","article-title":"Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay","volume":"215\u2013216","author":"Hou","year":"2015","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.antiviral.2018.11.001_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11262-009-0440-4","article-title":"Detection of non-polio enteroviruses in Hungary 2000-2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30","volume":"40","author":"Kapusinszky","year":"2010","journal-title":"Virus Gene."},{"key":"10.1016\/j.antiviral.2018.11.001_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jit429","article-title":"Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled trial","volume":"209","author":"Li","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.001_bib10","article-title":"In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model","volume":"9","author":"Li","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.11.001_bib11","article-title":"Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China","volume":"9","author":"Liu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.11.001_bib12","doi-asserted-by":"crossref","first-page":"11967","DOI":"10.1128\/JVI.00902-12","article-title":"A neonatal mouse model of coxsackievirus A16 for vaccine evaluation","volume":"86","author":"Mao","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4161\/hv.27087","article-title":"Coxsackievirus A16: epidemiology, diagnosis, and vaccine","volume":"10","author":"Mao","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.antiviral.2018.11.001_bib14","first-page":"8194","article-title":"Bispecific digoxigenin-binding antibodies for targeted payload delivery","volume":"vol. 108","author":"Metz","year":"2011"},{"key":"10.1016\/j.antiviral.2018.11.001_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2015.05.004","article-title":"Therapeutic antibodies: discovery, design and deployment","volume":"67","author":"Ramsland","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4161\/mabs.27385","article-title":"A new class of bispecific antibodies to redirect T cells for cancer immunotherapy","volume":"6","author":"Rossi","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2018.11.001_bib17","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1128\/AAC.00215-10","article-title":"Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains","volume":"55","author":"Schanzer","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.001_bib18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/19420862.2016.1147640","article-title":"Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2","volume":"8","author":"Scheuer","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2018.11.001_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4161\/mabs.26307","article-title":"Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity","volume":"5","author":"Shatz","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.antiviral.2018.11.001_bib20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/19420862.2016.1148850","article-title":"A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion","volume":"8","author":"Shi","year":"2016","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.antiviral.2018.11.001_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nbt.2621","article-title":"Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies","volume":"31","author":"Spiess","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2018.11.001_bib24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4161\/mabs.26390","article-title":"A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity","volume":"5","author":"Tan","year":"2013","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.antiviral.2018.11.001_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1405","article-title":"Eradication of established tumors in mice by a combination antibody-based therapy","volume":"12","author":"Uno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.11.001_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2249.1994.tb06517.x","article-title":"Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment","volume":"95","author":"van den Berg","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.002","article-title":"A human Bi-specific antibody against Zika virus with high therapeutic potential","volume":"171","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.11.001_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"Wu","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib29","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.vaccine.2017.03.065","article-title":"A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.11.001_bib30","doi-asserted-by":"crossref","first-page":"12973","DOI":"10.1038\/srep12973","article-title":"A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.11.001_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1743-422X-9-8","article-title":"Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications","volume":"9","author":"Xu","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.11.001_bib32","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1016\/j.vaccine.2016.10.018","article-title":"A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice","volume":"34","author":"Yang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.11.001_bib33","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s00253-016-7296-z","article-title":"Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles","volume":"100","author":"Ye","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.11.001_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7774\/cevr.2017.6.1.4","article-title":"Enterovirus 71 infection and vaccines","volume":"6","author":"Yi","year":"2017","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.antiviral.2018.11.001_bib35","article-title":"Severe hand-foot-and-mouth disease caused by mixed infection of enterovirus 71 and coxsackie A16: reports of 6 cases","volume":"14","author":"Zhang","year":"2011","journal-title":"Chin. Gen. Pract."},{"key":"10.1016\/j.antiviral.2018.11.001_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-422X-7-94","article-title":"An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China","volume":"7","author":"Zhang","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.11.001_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/protein\/13.5.361","article-title":"An efficient route to the production of an IgG-like bispecific antibody","volume":"13","author":"Zuo","year":"2000","journal-title":"Protein Eng."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:45:00Z","timestamp":1565261100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218304637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":37,"alternative-id":["S0166354218304637"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}